

Brilliant Violet 510™ anti-mouse CD21/CD35 (CR2/CR1)

Catalog # / Size: 1217185 / 50 µg

Clone: 7E9

Isotype: Rat IgG2a, κ


Immunogen: CD35/CFA

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Concentration: 0.2 mg/mL



C57BL/6 splenocytes were stained with CD45R/B220 PE and CD21/CD35 (CR2/CR1) (clone 7E9) Brilliant Violet 510™ (left) or rat IgG2a, κ isotype control Brilliant Violet 510™ (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

- Application References:**
1. Boackle S, et al. 2001 *Immunity* 15:775.
 2. de Andres B, et al. 2012. *J. Immunol.* 189:2300. [PubMed](#)
 3. Chiu YK, et al. 2014. *J Immunol.* 193:2207. [PubMed](#)
 4. Koenig PA, et al. 2014. *J Biol Chem.* 289:34490. [PubMed](#)

- Description:** CD21, also known as CR2 (complement receptor 2) and C3d receptor, binds C3d and iC3b. It is also a receptor of Epstein-Barr virus. CD35, also known as CR1, binds C3b, iC3b, C4b, and iC4b. CD21/CD35 is primarily expressed on B lymphocytes, mast cells, follicular dendritic cells, macrophages, and activated granulocytes. CD21/CD35 forms part of the B-cell antigen receptor complex with CD19 and CD81 and is involved in signal transduction.
- Antigen**
- References:**
1. Kozono Y, *et al.* 1998. *J. Immunol.* 160:1562.
 2. Shimizu I, *et al.* 2007. *Blood* 109:1773.
 3. Roozendaal R and MC. Carroll. 2007. *Immunol. Rev.* 219:157.